Co-delivery of chimeric peptide vaccine and CpG ODN adjuvant using PLGA nanospheres: Antibody responses against HTLV-۱

In the present investigation, the immunogenicity of HTLV-۱ fusion epitope-loaded PLGA nanoparticles (NPs) was assessed in the presence of co-encapsulated CpG ODN adjuvant, in a mice model. Accordingly, the recombinant vaccine containing Tax, env, and gag epitopes was encapsulated in PLGA nanoparticles (NPs) with CpG ODN adjuvant to assess the immune efficacy of various formulations in an animal model followed by subcutaneous or nasal administration. PLGA NPs were prepared using a double emulsion method with a size of approximately ۱۹۰ nm and the encapsulation efficiency was calculated ۸۳.۹%. The release profile of radiolabeled chimera indicated that ۲۰% of chimera were released from PLGA NPs during one month. Co-encapsulation of chimera and CpG in PLGA NPs could considerably elicit cell-mediated responses compared to the incorporation of CpG and chimera antigen solution. These findings revealed that the co-delivery of recombinant vaccine and CpG adjuvant using PLGA NPs could induce potent cell-mediated and mucosal immunity without inflammatory responses against HTLV-۱. Hence, an appropriate vaccine design and immunization strategy are essential parameters to construct an effective vaccine.

کلیدواژه ها:

Chimeric peptide vaccine ، PLGA ، CpG adjuvant ، Cellular response ، Mucosal immunity ، Antibody assay ، HTLV-۱.